EA201300857A1 - Пиразолы в качестве антагонистов crth2 - Google Patents

Пиразолы в качестве антагонистов crth2

Info

Publication number
EA201300857A1
EA201300857A1 EA201300857A EA201300857A EA201300857A1 EA 201300857 A1 EA201300857 A1 EA 201300857A1 EA 201300857 A EA201300857 A EA 201300857A EA 201300857 A EA201300857 A EA 201300857A EA 201300857 A1 EA201300857 A1 EA 201300857A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrazoles
compounds
crth2
antagonists
antagonists crth2
Prior art date
Application number
EA201300857A
Other languages
English (en)
Other versions
EA022559B1 (ru
Inventor
Ральф Андерскевитц
Домник Мартирес
Торстен Ост
Вольфганг Рист
Петер Зайтер
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43799503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201300857(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201300857A1 publication Critical patent/EA201300857A1/ru
Publication of EA022559B1 publication Critical patent/EA022559B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к пиразолам формулы (Ia) или (Ib) и их фармацевтически приемлемым солям, в которых R, R, R, R, Y, Y, Y, Y, Y, Z, R, R, n и Rимеют одно из значений, приведенных в описании и формуле изобретения, к их применению в качестве лекарственных средств, к фармацевтическому составу, содержащему указанные соединения, и к фармацевтическим составам, содержащим указанные соединения в комбинации с одним или несколькими активными веществами. Эти соединения обладают антагонистической активностью по отношению к CRTH2.
EA201300857A 2011-01-24 2012-01-20 Пиразолы в качестве антагонистов crth2 EA022559B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11151876 2011-01-24
PCT/EP2012/050830 WO2012101043A1 (en) 2011-01-24 2012-01-20 Pyrazole compounds as crth2 antagonists

Publications (2)

Publication Number Publication Date
EA201300857A1 true EA201300857A1 (ru) 2013-12-30
EA022559B1 EA022559B1 (ru) 2016-01-29

Family

ID=43799503

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300857A EA022559B1 (ru) 2011-01-24 2012-01-20 Пиразолы в качестве антагонистов crth2

Country Status (36)

Country Link
US (1) US8759386B2 (ru)
EP (1) EP2668181B1 (ru)
JP (1) JP5695216B2 (ru)
KR (2) KR101923365B1 (ru)
CN (4) CN104628705B (ru)
AP (1) AP3343A (ru)
AR (1) AR084916A1 (ru)
AU (1) AU2012210718B2 (ru)
BR (1) BR112013017570B1 (ru)
CA (1) CA2825458C (ru)
CL (1) CL2013001945A1 (ru)
CO (1) CO6801731A2 (ru)
CY (1) CY1116012T1 (ru)
DK (1) DK2668181T3 (ru)
EA (1) EA022559B1 (ru)
EC (1) ECSP13012832A (ru)
ES (1) ES2529452T3 (ru)
GE (1) GEP20156332B (ru)
HK (3) HK1186183A1 (ru)
HR (1) HRP20150069T1 (ru)
IL (1) IL226920A (ru)
MA (1) MA34838B1 (ru)
MX (1) MX342830B (ru)
MY (1) MY163012A (ru)
PE (1) PE20140860A1 (ru)
PH (1) PH12018501531A1 (ru)
PL (1) PL2668181T3 (ru)
PT (1) PT2668181E (ru)
RS (1) RS53785B1 (ru)
SG (1) SG192096A1 (ru)
SI (1) SI2668181T1 (ru)
TN (1) TN2013000280A1 (ru)
TW (1) TWI527809B (ru)
UA (1) UA109696C2 (ru)
UY (1) UY33873A (ru)
WO (1) WO2012101043A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759386B2 (en) * 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
EP2688882B1 (en) * 2011-03-25 2015-05-13 Boehringer Ingelheim International GmbH Pyrazole compounds as crth2 antagonists
US20140148484A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
WO2014079803A1 (en) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Bicyclosubstituted pyrazole compounds for treating hairloss
EP3768245A4 (en) * 2018-03-23 2023-10-18 Palatin Technologies, Inc. MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDE FORMULATIONS AND METHODS OF ADMINISTRATION SPECIFIC TO THE GASTROINTESTINAL TRACT
CN113874015B (zh) 2018-12-21 2024-05-24 细胞基因公司 Ripk2的噻吩并吡啶抑制剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
PL356487A1 (en) 1999-11-10 2004-06-28 Takeda Chemical Industries, Ltd. 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
JP2007509104A (ja) * 2003-10-24 2007-04-12 グラクソ グループ リミテッド 複素環式化合物
CN101084209A (zh) * 2004-12-21 2007-12-05 德福根有限公司 具有Kv4离子通道活性的化合物
JP4950542B2 (ja) * 2006-04-07 2012-06-13 岩手東芝エレクトロニクス株式会社 固体撮像装置およびその製造方法
WO2007141267A1 (en) 2006-06-06 2007-12-13 Glaxo Group Limited N- (phenylmethyl) -2- (1h-pyraz0l-4-yl) acetamide derivatives as p2x7 antagonists for the treatment of pain, inflammation and neurodegeneration
EP2097407A1 (en) * 2006-11-27 2009-09-09 Pfizer Products Inc. Pyrazole analogs
MX2010003178A (es) * 2007-09-25 2010-04-30 Actimis Pharmaceuticals Inc Primidinas sustituidas con 2-s-bencilo como antagonistas de crth2.
TW200922587A (en) 2007-09-25 2009-06-01 Actimis Pharmaceuticals Inc Alkylthio pyrimidines as CRTH2 antagonists
JP2011088826A (ja) * 2008-01-31 2011-05-06 Astellas Pharma Inc 芳香族カルボン酸化合物
US20110144160A1 (en) * 2008-07-03 2011-06-16 Amira Pharmaceuticals, Inc. Antagonists of Prostaglandin D2 Receptors
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
WO2010089391A1 (en) * 2009-02-09 2010-08-12 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
AP3360A (en) * 2010-01-27 2015-07-31 Boehringer Ingelheim Int Pyrazole compounds as CRTH2 antagonists
EP2598145A1 (en) * 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmaceutical composition for treatment of respiratory and inflammatory diseases
US8759386B2 (en) * 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists

Also Published As

Publication number Publication date
JP5695216B2 (ja) 2015-04-01
UA109696C2 (xx) 2015-09-25
CN104961732B (zh) 2017-07-11
AP3343A (en) 2015-07-31
KR20140005931A (ko) 2014-01-15
CO6801731A2 (es) 2013-11-29
AU2012210718B2 (en) 2016-06-02
TWI527809B (zh) 2016-04-01
RS53785B1 (en) 2015-06-30
PH12018501531A1 (en) 2019-04-08
CA2825458C (en) 2021-01-26
CN103339125A (zh) 2013-10-02
BR112013017570B1 (pt) 2022-01-11
AU2012210718A1 (en) 2013-07-04
CN104628705B (zh) 2017-04-12
EP2668181A1 (en) 2013-12-04
HK1215247A1 (zh) 2016-08-19
MX342830B (es) 2016-10-14
BR112013017570A2 (pt) 2016-10-18
NZ611695A (en) 2015-04-24
PL2668181T3 (pl) 2015-04-30
CY1116012T1 (el) 2017-01-25
HK1186183A1 (en) 2014-03-07
AP2013006942A0 (en) 2013-06-30
SI2668181T1 (sl) 2015-02-27
ES2529452T3 (es) 2015-02-20
CN103339125B (zh) 2015-07-15
CN107011332A (zh) 2017-08-04
CA2825458A1 (en) 2012-08-02
US20130023576A1 (en) 2013-01-24
EA022559B1 (ru) 2016-01-29
UY33873A (es) 2012-07-31
MA34838B1 (fr) 2014-01-02
GEP20156332B (en) 2015-07-27
TN2013000280A1 (en) 2014-11-10
IL226920A (en) 2016-11-30
CL2013001945A1 (es) 2013-10-25
PT2668181E (pt) 2015-02-05
DK2668181T3 (da) 2015-01-19
HRP20150069T1 (hr) 2015-02-27
CN104628705A (zh) 2015-05-20
CN104961732A (zh) 2015-10-07
KR101923365B1 (ko) 2018-11-30
PE20140860A1 (es) 2014-07-20
MY163012A (en) 2017-07-31
AR084916A1 (es) 2013-07-10
WO2012101043A1 (en) 2012-08-02
CN107011332B (zh) 2020-03-13
SG192096A1 (en) 2013-08-30
MX2013008082A (es) 2013-09-13
ECSP13012832A (es) 2013-09-30
HK1210467A1 (en) 2016-04-22
KR102251939B1 (ko) 2021-05-14
KR20180129962A (ko) 2018-12-05
US8759386B2 (en) 2014-06-24
EP2668181B1 (en) 2014-11-05
TW201245184A (en) 2012-11-16
JP2014502986A (ja) 2014-02-06

Similar Documents

Publication Publication Date Title
EA201401351A1 (ru) Производные бензимидазол-пролина
CY1123365T1 (el) Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
TR201904614T4 (tr) Novel pyrazole derivative.
EA201591662A1 (ru) Липиды и липидные композиции для доставки активных агентов
MA34069B1 (fr) Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a)
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
CR20130487A (es) 1,3-oxazinas como inhibidores de BACE1 y/o BACE2
EA201591195A1 (ru) Новые хинолоновые производные
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201490037A1 (ru) Антагонисты trpv4
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
PH12018501531A1 (en) Pyrazole compounds as crth2 antagonists
EA201501163A1 (ru) Модуляторы рецептора cxcr7
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
EA201290229A1 (ru) Производные спиролактама и их применение
CY1115600T1 (el) Πιπεραζινες ως ανθελονοσιακοι παραγοντες
EA201500313A1 (ru) Стабилизированная аморфная форма агомелатина, способ ее изготовления и фармацевтические композиции, ее содержащие
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title